All In Biotech

Drug Trial Radar · NCT03538028

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies

Last checked: Nov 20, 2026Latest source record: Oct 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

22

Actual

Start

Jun 18, 2018

Primary completion

Oct 7, 2020

Study completion Oct 7, 2020

Sponsor

Sponsor type
Industry
First posted
May 25, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.

Conditions

  • Cervical Cancer
  • Microsatellite Instability (MSI)-High Endometrial Cancer
  • Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])
  • Esophageal Cancer
  • Hepatocellular Carcinoma
  • Melanoma (Uveal Melanoma Excluded)
  • Merkel Cell Carcinoma
  • Mesothelioma
  • MSI-high Colorectal Cancer
  • Non-small Cell Lung Cancer (NSCLC)
  • Ovarian Cancer
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • Small Cell Lung Cancer (SCLC)
  • Renal Cell Carcinoma (RCC)
  • Triple-negative Breast Cancer
  • Urothelial Carcinoma
  • Diffuse Large B-cell Lymphoma

Interventions

  • INCAGN02385Biological

    INCAGN02385 administered as an intravenous infusion over 30 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of treatment-emergent adverse events (TEAEs)Time frame: Up to 12 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • The Angeles Clinic and Research Center

    Los Angeles, California

  • Hackensack Medical Center

    Hackensack, New Jersey

  • Carolina BioOncology Institute

    Huntersville, North Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.